Pharmaceuticals

New Pharma will crowd out Big Pharma

11 Jun 2024

For decades the likes of Pfizer have ruled the industry, gobbling up tech-driven players. But former upstarts are no longer bite-sized, as Vertex Pharmaceuticals’ $125 bln market cap proves. Their new strength will create more M&A competition and undermine established leaders.

Investors prescribe harsh medicine for GSK’s boss

3 Jun 2024

Shareholders wiped $9 bln off the UK drugmaker’s market value after a US judge approved lawsuits over heartburn drug Zantac. It may be an overreaction given the company’s win in another state and previous settlements. But it adds pressure on CEO Emma Walmsley’s turnaround plan.

AI will help treat Big Pharma’s looming illness

15 May 2024

Drug discovery is a long and costly process with success rates below 10%. Caps on prices and shorter patent periods in the US will also make life harder for the likes of Pfizer, AstraZeneca and rivals. Despite patchy results, betting on machines may be the best hope of a cure.

Anti-obesity drugmakers savor pandemic leftovers

1 May 2024

The main obstacle to Eli Lilly and Novo Nordisk selling more weight-loss treatments is the ability to produce them. It turns out Covid-vaccine infrastructure has useful capacity. Quickly solving supply concerns gives both a shot at bigger slugs of the potential $100 bln market.

Vote no to bashing proxy advisers

25 Apr 2024

Corporate leaders at JPMorgan and AstraZeneca bridle when ISS and Glass Lewis criticize their governance. No wonder: Some high-stakes shareholder votes this year will be uncomfortable for feather-bedded bosses. Proxy firms are problematic, but they do more good than harm.

Blackstone cures two ailments in one Moderna shot

27 Mar 2024

Higher costs of capital are pressuring CEOs into tough spending decisions, while buyout shops flush with cash want to deploy it. This dynamic makes a $750 mln deal to fund a biotech project a crafty solution. The hard end of the bargain: ceding value from promising flu research.

Capital Calls: Wegovy gets a booster

22 Mar 2024

Concise views on global finance: The US government’s decision to pay for weight-loss drugs for some older patients is a big step for makers Eli Lilly and Novo Nordisk. Not because it will boost their share prices, but because it makes current valuations less far-fetched.

Reckitt slump offers a cue to slim down

18 Mar 2024

The $41 bln Lysol maker’s shares fell sharply after it lost a US court case. One option for Reckitt Benckiser is to separate the nutrition arm, focus of the legal woes. That would ease the hit to the rest of the group, but also leave a new arm that may yet be worth something.

American healthcare is a perfect cyber-hostage

7 Mar 2024

A hack at the biggest processor of insurance claims snarled billions of dollars of payments to US hospitals. The healthcare system’s interdependent web of middlemen means none can be allowed to fail, making it an ever-more-obvious target for the growing onslaught of ransomware.

Galderma IPO offers EQT a temporary facelift

6 Mar 2024

The Swiss skin care group is looking to raise $2 bln in a listing to cut debt. At $22 bln, in line with L’Oréal’s valuation, its private equity owners could get decent returns. But with the French beauty giant growing similar products faster, retaining margins may be challenging.

Bayer’s inertia will make mounting problems worse

5 Mar 2024

The $30 bln seeds and drugs maker has ruled out a rapid breakup. Bayer could have used a consumer health sale to cut debt and offset bigger US litigation costs. Betting instead that it can grow its way out of trouble risks exacerbating a yawning discount to the sum of its parts.

Stolen razors are least of US drugstores’ concerns

1 Mar 2024

Walgreens and CVS have locked up items from deodorant to toothpaste. But a hyper-focus on theft is a reflection of drugstores’ more dire straits. Online competition, labor issues, and inflation are cutting into margins. Larceny is just the thing that pharmacies can control.

Europe shares’ granola rush will become thin gruel

26 Feb 2024

The STOXX 600 Index has hit a record, but local funds are seeing outflows. As in the US a small bunch of companies – the so-called GRANOLAS group – are behind the good news. But in the Old Continent they’re more dependent on weak economic growth rather than the AI revolution.

Too many drugmakers drool at anti-obesity trough

21 Feb 2024

Novo Nordisk’s and Eli Lilly’s jumbo valuations are luring rivals eager for a piece of the $100 bln weight-loss pie. This herd behavior has become a pattern in pharma, crimping returns on R&D. Despite slim odds of getting a big market slice, the temptation is too hard to resist.

The obesity drug craze is entering its next phase

8 Feb 2024

Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world.

Novo digs $11.5 bln moat around weight-loss jewel

5 Feb 2024

The pharma giant’s parent is buying US manufacturer Catalent. It helps Novo Nordisk keep up with soaring demand for obesity drugs, and makes it harder for rival Eli Lilly to catch up. With such limited capacity, Catalent’s rivals like $4 bln ROVI may soon be in play.

Capital Calls: Disney virtual reality

23 Jan 2024

Concise views on global finance: The $174 bln entertainment giant introduced a novel way for consumers to experience its brands through a partnership with Apple. Further connecting the dots between theme parks and the metaverse might bide Iger some time.

Obesity drug firms choose golden goose pricing

18 Jan 2024

Eli Lilly and Novo Nordisk can’t keep up with demand for weight loss drugs, yet they are offering big discounts to those whose insurance won’t help pay. That probably will harvest more eggs over time.

Capital Calls: Spanish pharma

9 Jan 2024

Concise views on global finance: Shares in Madrid-listed drugmaker Grifols fell up to 42% after Gotham City Research alleged that the company’s already elevated debt levels were higher than previously reported.

Rich nations can learn from Ireland’s health shift

9 Jan 2024

Dublin wants to build a universal healthcare system. Phasing out a US-like insurance model is bold and could require 20 bln euros from the state. Countries thinking of similar overhauls to deal with waiting lists and ageing citizens will need money and political consensus.